Pharma Consolidation

Pharma Dealmaking Heats Up With J&J and Lilly Acquisitions

By Finks Desk
Pharma Dealmaking Heats Up With J&J and Lilly Acquisitions

Two pharmaceutical buyers began the week by paying up for medicines that will not reach the market for years.

Johnson & Johnson said Monday it will pay $2.2B upfront for Ollin Biosciences, a Texas biotech whose retinal drug is in Phase 3 testing, plus further payments if the treatment clears regulatory and commercial milestones.

The total reaches about $3.3B, and J&J expects to close before the end of 2026.

OLN324 is a bispecific antibody that blocks vascular endothelial growth factor and angiopoietin-2, the same two proteins targeted by Roche's Vabysmo. It is being developed for diabetic macular edema and wet age-related macular degeneration, conditions J&J says affect more than 40M people worldwide.

Blackstone ($BX) Life Sciences will pay J&J $750M over several years to fully fund Phase 3 development, in return for milestone payments and single digit royalties.

The company is buying its way into retinal drugs

J&J's eye business runs on contact lenses, intraocular lenses and surgical equipment, and it does not sell a retinal drug today.

Ollin, backed by ARCH Venture Partners, raised $330M in June and licensed OLN324 from Shanghai-based Innovent Biologics.

In the mid-stage JADE trial, Ollin says OLN324 produced faster and greater improvements in retinal anatomy than Vabysmo, along with greater vision gains.

Four Phase 3 studies are running, two in wet age-related macular degeneration and two in diabetic macular edema, each measured against Lucentis or Eylea.

Ollin's other asset, OLN102, targets thyroid eye disease and is still preclinical.

RBC Capital Markets analyst Trung Huynh called the deal a logical strategic fit given J&J's eye care presence, while questioning how differentiated the drug is in a crowded field.

"OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control."

Kip Connor, Johnson & Johnson

A busy Monday for pharma dealmaking

Eli Lilly agreed the same morning to buy Calytrix Bio for up to $1.5B in cash, an upfront payment plus clinical and regulatory milestones.

Calytrix's lead program is a preclinical biparatopic antibody aimed at mutated calreticulin, a genetic alteration that drives essential thrombocythemia and myelofibrosis.

It has not entered human trials, which makes it an early bet even by biotech standards.

Two Pharma Buyers Committed About $4.8B in One Morning

Maximum total deal value announced Nov 16, 2026, billions of dollars

Bar chart. Total Value ($B). J&J / Ollin Biosciences: Deal Value ($B) $3.3. Eli Lilly / Calytrix Bio: Deal Value ($B) $1.5.

Source: Company releases, Nov 16, 2026

It follows the $2.3B acquisition of Ajax Therapeutics earlier this year, another blood cancer bet, as Lilly works to diversify beyond its diabetes and weight loss franchise.

Current treatments for the two blood disorders mainly manage symptoms rather than target the cells driving them.

Blackstone has also been funding late-stage pharma bets, including an offer of up to $1.5B to Pfizer last week for an obesity drug. Both buyers are paying for science that still has to clear the clinic, and neither drug has an approval date.